Actinogen Medical targets November XanaMIA results highlighting strong June quarter

Actinogen Medical Ltd managing director and CEO Dr Steven Gourlay talked with Proactive about the company’s June quarter progress, including preparations for the pivotal XanaMIA Alzheimer’s disease trial topline results expected in November 2026. Gourlay said the fully enrolled Phase 2b/3 trial remained on schedule, with treatment, follow-up and data-cleaning activities continuing across participating sites. He described the upcoming readout as “a potentially transformational event for the company and for the clinical science, and for patients with Alzheimer’s all around the world.” An independent Data Monitoring Committee completed its third review of safety data from all 247 trial participants and recommended that the study continue without amendment. Actinogen Medical ended the quarter with $16.7 million in cash. Chief Financial Officer Will Souter said the company’s current funding position was expected to support operations beyond the XanaMIA results and into mid-2027. He also highlighted potential additional funding sources, including an anticipated research and development tax rebate and the possible exercise of listed and unlisted options. Gourlay also discussed positive depression trial data published in the British Journal of Psychiatry and the company’s continuing engagement with regulators, including the US Food and Drug Administration and the European Medicines Agency. Visit Proactive’s YouTube channel for more company interviews and market updates. Please give the video a like, subscribe to the channel and enable notifications for future content.